Navigation Links
Cobalis Corp. Launches National Television Commercials for PreHistin® Allergy Defense Formula
Date:5/10/2011

IRVINE, Calif., May 10, 2011 /PRNewswire/ -- Cobalis Corp. (CLSC.PK) announced today they have started airing 60-second television commercials for PreHistin® Allergy Defense Formula, on major national cable and satellite networks across the US.

The commercials, featuring leading US allergist Dr. Paul H. Ratner, MD, explain how PreHistin works at the root cause of allergies, giving seasonal and year-round sufferers the first truly new advance in allergies in many years -- a safe and effective, side-effect free, all natural product intended, in the words of Dr. Ratner, to "help restore a normal response to seasonal and year-round allergies, which is no allergic response at all!"

The commercials were created to help build the PreHistin brand to consumers and allergy sufferers, and drive traffic to the pharmacy retailers across the US who now carry PreHistin in their allergy section. The commercials are now being placed on national cable networks and satellite cable providers, in a planned $5 million TV advertising campaign reaching a daily audience of over 300 million Americans, such as ION, Reelz, Great American Country, Style, Cooking Channel, ABC Family, BBC, BIO, OWN, E!, Lifetime, Oxygen, Soapnet, Womens' Entertainment, Style and many others.

The spots not only present the PreHistin story and explain the real cause of allergies, but prompt viewers that PreHistin is available now at fine pharmacies everywhere, and to "ask your pharmacist for PreHistin today."

Marty Marion, Cobalis CEO said, "We are excited to announce the start of our national TV campaign for PreHistin, which was selected as "Best New Product of 2011" out of a field of over a thousand products at the recent ECRM Cough, Cold and Allergy show. We are committed to supporting those retailers and pharmacies who are selling PreHistin, and television is just one of the support channels we are engaging to drive traffic, stimulate brand awareness and increase sales."

Cobalis President Chas Radovich said, "We believe that when allergy sufferers learn the PreHistin story they will try PreHistin for its ability to naturally restore a normal non-reactive response to allergens with no side effects or sedation. We thank the retailers who have brought PreHistin into their stores, and who are partnering with us to build PreHistin into a national brand."

PreHistin is now on shelves at one of the nation's two largest drugstore chains, as well as many fine regional and local pharmacies, and is expected to be on the shelf at most pharmacy and grocery shelves across the country very quickly.

ABOUT PREHISTIN® ALLERGY DEFENSE FORMULA

PreHistin® Allergy Defense Formula is a patented cobalamin complex that helps rebalance the immune system to lower allergen antibody IgE levels, and regulate the release of symptom-linked histamine. PreHistin is a cherry-flavored lozenge dissolved under the tongue and then swallowed twice a day, usually starting before the allergy season, or taken daily for those suffering from year-round allergies. PreHistin has no known side effects, is 100% non-drowsy, and has no contraindications with any other medications. In clinical trials on thousands of allergy sufferers, PreHistin was shown to be safe and effective in reducing nasal symptoms.

ABOUT COBALIS CORP. -- PREHISTIN®

Cobalis Corp. is a specialty pharmaceutical, nutraceutical and preventive healthcare product development and marketing company. Its flagship product, PreHistin® Allergy Defense Formula, "The World's First Pre-Histamine", is designed to mitigate overproduction of IgE levels and restore a normal response to seasonal and year-round indoor and outdoor allergens. PreHistin is now available without prescription for both long-term and daily use.

For PreHistin product information please visit http://www.PreHistin.com or call toll free 1-877-4POLLEN (1-877-476-5536). For additional company information please visit the corporate website at http://www.Cobalis.com

CONTACT

Cobalis Corp.
16795 Von Karman, Suite 200
Irvine, CA 92606
949-260-0123 (pacific time)

Chas Radovich, President
Martin Marion, CEO
info@cobalis.com


'/>"/>
SOURCE Cobalis Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cobalis Corp. Receives $415,000 First Purchase Order from Major Retail Pharmacy for PreHistin® Allergy Defense Formula
2. Cobalis Corp. Announces Second Update Conference Call for Investors on October 5, 2010
3. Cobalis Corp. Provides Marketing Update Conference Call for Investors
4. BAETA Corp. Expands Market Awareness Programs
5. ThermoGenesis Corp. to Announce Third Quarter Fiscal 2011 Results On May 5, 2011
6. Immune Design Corp. Appoints Pharma and Biotech Executive Carlos V. Paya, MD, PhD as Chief Executive Officer
7. Oxford Finance Corporation Provides a $2 Million Equipment Facility to Synta Pharmaceuticals Corp.
8. BioSpecifics Technologies Corp. Announces Launch of XIAPEX® by Pfizer for Treatment of Dupuytrens Contracture in Europe
9. Cantel Medical Corp. to Present at the Needham & Company 10th Annual Healthcare Conference
10. NephRx Corp. Awarded U.S. Patent for Use of Novel Growth Factor Peptide NX002 in Inflammatory Bowel Disease
11. NephRx Corp. Awarded New U.S. Patent for Oral Mucositis Agent NX002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , March 29, 2017 Avelas Biosciences, Inc., a ... diagnosis through treatment, today announced that Carmine N. Stengone , ... company at the Needham & Company 16 th Annual Healthcare ... a.m. PDT) at the Westin Grand Central Hotel in ... ...
(Date:3/29/2017)... 2017 Research and Markets has announced the addition ... Centers & Forecast" report to their offering. ... Proton Therapy Market in Italy ... in 2016. There are currently three proton therapy centers in ... patients. In Italy , the first patients were treated ...
(Date:3/29/2017)... , Mar. 29, 2017 Research and Markets has ... Policy, Patients Treated at Proton Therapy Centers & Forecast" report to ... The South ... its current market size in 2016. The Untapped Proton Therapy Market for ... Billion USD in 2016. Proton Therapy plays an important ...
Breaking Medicine Technology:
(Date:3/29/2017)... Amherst, Massachusetts (PRWEB) , ... March 30, 2017 , ... ... has had great success and feedback from high school and college students who have ... is being held July 7-23 and YFI is now accepting applications for enrollment. ...
(Date:3/29/2017)... (PRWEB) , ... March 30, 2017 , ... Sports Brand ... brace, which retails normally at $29.97; for the remaining days of March, the ... also been reduced to a special price of just $10 (regular retail price $19.97). ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... at a Walgreens store in Mississippi. AngioGenesis Labs, makers of HeartBoost, BrainBest and ... two southeastern states. Ingredients in HeartBoost, an over the counter heart healthy drink, ...
(Date:3/29/2017)... ... 2017 , ... Based on research from Guardian’s Fourth Annual ... trying to balance both short-term and long-term benefits demands. Are employers struggling ... complexity, companies are finding that the short-term strategies used to control costs, improve ...
(Date:3/29/2017)... Horeb, WI (PRWEB) , ... March 29, 2017 , ... ... patients on early orthodontic treatment and accepting new pediatric patients, with or without a ... help young patients have a better orthodontic outcome and experience. When patients receive early ...
Breaking Medicine News(10 mins):